Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 17/20 | 0.68 |
| ▸ | RAB9A | P51151 | 17/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 16/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.68 |
| ▸ | HTT | P42858 | 3/20 | 0.66 |
| ▸ | TSHR | P16473 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | TP53 | P04637 | 6/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.62 |
| ▸ | RELA | Q04206 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 3/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | GRM5 | P41594 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8900290 | 0.83 | NPC1 (0.68) | NPC1RAB9ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL7976807 | 0.81 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL11947463 | 0.81 | NPC1 (0.71) | NPC1RAB9ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL12611947 | 0.80 | NPC1 (0.42) | NPC1RAB9ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL21296247 | 0.79 | GRM5 (0.66) | NPC1RAB9ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL4034138 | 0.78 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL4109085 | 0.78 | NPC1 (0.80) | NPC1RAB9ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL26525964 | 0.78 | NPC1 (0.72) | NPC1RAB9ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL4037120 | 0.78 | NPC1 (0.72) | NPC1RAB9ASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL6384896 | 0.77 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662180-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-10662180-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-05-26 | — | — | US | disclosed |
| US-20180215742-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215742-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215742-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-9878999-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878999-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878999-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| EP-2375899-B1 | PIPERIDINE-CONTAINING COMPOUNDS AND USE THEREOF IN THE TREATMENT OF DIABETES | ARRAY BIOPHARMA INC (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8809538-B2 | Piperidine-containing compounds and use thereof | ARRAY BIOPHARMA INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-7148226-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2006-08-24 | — | — | US | disclosed |
| EP-1597246-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2005-08-11 | — | — | US | disclosed |
| WO-2004074270-A2 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| EP-0222576-B1 | HETEROCYCLIC OXOPHTHALAZINYL ACETIC ACIDS | PFIZER INC. (US) | 1992-03-18 | — | — | EP | disclosed |
| US-4939140-A | ALDOSE REDUCTASE INHIBITORS | PFIZER INC. (US) | 1990-07-03 | — | — | US | disclosed |
| EP-0222576-A2 | Heterocyclic oxophthalazinyl acetic acids | PFIZER INC. (US) | 1987-05-20 | — | — | EP | disclosed |
| US-RE32154-E | FROM BENZO-THIETANE-2-SPIRO-2'(1,3'-DIZACCYCLOALKANE AND ALKYL HALIDE | BASF AKTIENGESELLSCHAFT (DE) | 1986-05-20 | — | — | US | disclosed |
| US-4122263-A | REACTING A BENZOTHIETANE-2-SPIRO-2'(1',3'-DIAZACYCLOALKANE) WITH AN ALKYL HALIDE | BASF AKTIENGESELLSCHAFT (DE) | 1978-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662180-B2 | Proteasome chymotrypsin-like inhibition using PI-1833 analogs | PSMB3, PSME3, PSMD3 | NPC1 2728/4885RAB9A 3319/4885SMN1; SMN2 3198/4885 |
| US-20180215742-A1 | PROTEASOME CHYMOTRYPSIN-LIKE INHIBITION USING PI-1833 ANALOGS | PSMB3, PSME3, PSMD3 | NPC1 2728/4885RAB9A 3319/4885SMN1; SMN2 3198/4885 |
| US-20060189681-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, RNASEH1, NSUN3 | NPC1 110/4885RAB9A 3188/4885SMN1; SMN2 3095/4885 |
| US-20050176701-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, RNASEH1, NSUN3 | NPC1 110/4885RAB9A 3188/4885SMN1; SMN2 3095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.